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Abstract Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635)
is an orally active multi-targeted receptor tyrosine kinase inhibitor for the
treatment of various cancers. It was being developed by Roche but develop-
ment has now reverted to Abbott. The compound is designed to inhibit
vascular endothelial growth factor and platelet-derived growth factor recep-
tors. It is in phase III development for liver cancer and phase II development
for non-small cell lung cancer, breast cancer, and colorectal cancer in the US,
the EU and other areas of the world. This review discusses the key develop-
ment milestones and therapeutic trials of this drug.
1. Introduction
Abbott Laboratories is developing linifanib,
an orally active multi-targeted receptor tyrosine
kinase inhibitor, for the treatment of cancer, in-
cluding non-small cell lung cancer (NSCLC),
breast cancer, liver cancer, and colorectal cancer.
Linifanib was being developed in collaboration
with Genentech, a member of the Roche Group;
however, according to Roche’s 2009 results pre-
sentation, development has reverted to Abbott.
The compound is designed to inhibit vascular
endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) receptors. Linifa-
nib is hydrophobic, but is oxidized in the body to
A 849529, a hydrophilic metabolite that includes
both carboxyl and amino groups. Linifanib is in
phase II development for breast, renal, colorectal,
and NSCLC, and is being assessed in a phase III
clinical trial for the treatment of liver cancer.
1.1 Company Agreements
Abbott and Genentech entered into a global
research, development, and commercialization
agreement for two of Abbott’s investigation anti-
cancer compounds, linifanib, and ABT 263, in
June 2007. However, according to Roche’s 2009
results presentation, development of the com-
pound has reverted to Abbott, and the agreement
appears to have been terminated. Under the
terms of the agreement, the companies were
to work together on all aspects of further devel-
opment and commercialization of the com-
pounds. Both companies would co-promote any
resulting products in the US and Abbott would
promote any resulting products outside of this
market. Financial terms of the agreement were
not disclosed.[1]
1.2 Key Development Milestones
1.2.1 Breast Cancer
In March 2010, Abbott completed a random-
ized phase II trial (NCT00645177) of linifanib in
combination with paclitaxel as first-line therapy
in patients with advanced breast cancer. The trial
included an open-label lead-in portion to assess
the tolerability and pharmacokinetic interactions
of 0.20mg/kg once-daily linifanib and paclitaxel
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(90mg/m2) in approximately 6–12 patients.
Enrollment into the randomized portion began
after the cohorts completed two cycles (8 weeks)
of therapy without unacceptable toxicity. In the
randomized portion, paclitaxel was given as a 1-hour
infusion at 90mg/m2/week, every 3 out of 4 weeks.
Linifanib was administered at 0.20mg/kg/day
once daily. The trial enrolled 102 patients in the
US and Mexico.
Preliminary results from the non-randomized
portion have been reported.[2]
1.2.2 Colorectal Cancer
Abbott has initiated a phase II study (NCT-
00707889) to determine the effect of linifanib in
combination with mFOLFOX6, compared with
bevacizumab with mFOLFOX6, for the second-
line treatment of advanced colorectal cancer.
This trial will enroll approximately 147 patients
in the US, the EU, Canada, South Korea, and
Australia.
1.2.3 Hepatocellular Carcinoma (Liver Cancer)
Genentech and Abbott initiated a phase III
clinical trial (NCT01009593) to assess the efficacy
and tolerability of linifanib in patients with hep-
atocellular carcinoma. This trial will enroll ap-
proximately 900 subjects from the US, Australia,
the EU (Belgium, Czech Republic, Denmark,
France, Germany, Italy, the Netherlands, Spain),
Canada, Egypt, Japan, South Korea, Malaysia,
Norway, Singapore, and Taiwan. The primary
endpoint will be overall survival while the
secondary endpoints include time to disease pro-
gression and objective response rate.
An open-label phase II clinical trial (NCT-
00517920) is taking place with linifanib in the US,
Canada, Hong Kong, Singapore, and Taiwan, in
44 patients with advanced hepatocellular carcino-
ma. Results have been presented.[3]
1.2.4 Non-Small Cell Lung Cancer
Linifanib is in a phase II clinical trial
(NCT00517790) in patients with advanced
NSCLC treated with at least one, but no more
than two, prior lines of systemic treatment. The
trial is taking place in the US, Canada, France,
Sweden, Singapore, and Taiwan and enrolled 139
patients. Results have been presented.[4,5]
Another phase II study (NCT00716534) is
investigating the clinical efficacy and toxicity of
linifanib in combination with carboplatin and
paclitaxel as first-line therapy in approximately
120 patients with advanced or metastatic NSCLC
in the US, Australia, Brazil, the Czech Republic,
Russia, and Singapore.
1.2.5 Renal Cell Carcinoma (RCC)
A phase II clinical trial (NCT00486538) is
underway in the US and Canada with linifanib
in 53 patients with advanced RCC who have
previously received treatment with sunitinib.
Efficacy and safety results have been reported.
In succeeding monotherapy trials, the fixed
starting dose of linifanib to be used would be
17.5mg/day.[6]
1.2.6 Solid Tumors
Abbott is conducting a phase I trial
(NCT01114191) to determine the interaction of
ketoconazole with linifanib in 12 subjects in
the US. The company also has an ongoing
pharmacokinetic phase I study (NCT00733187)
evaluating effect of food and diurnal variation
on linifanib in 12 patients with advanced or
metastatic solid tumors in the US. A phase I
study (NCT00718380) is evaluating the pharmaco-
kinetics, safety, and tolerability of linifanib
(2.5mg or 10mg) in 18 patients with solid tumors
in Japan.
1.2.7 Acute Myeloid Leukemia
Results from preclinical trials have shown lini-
fanib to induce apoptosis of FLT-3 ITD mutant
cells both in vitro and in vivo. These studies sug-
gest that linifanib may demonstrate potential to-
wards the treatment of acute myeloid leukemia in




Phase II : In a phase II trial in patients with
refractory solid tumors who received linifanib
once daily in 21-day treatment cycles, the fol-
lowing pharmacokinetic parameters were ob-
served for drug doses of 0.10mg/kg (n= 11) versus
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0.25mg/kg (n = 12): time to maximum plasma
concentration (Cmax) 3.5 versus 2.7 h; elimination
half-life 19.0 versus 18.9 h; clearance 2.3 versus
3.0 L/h; and dose-normalized steady-state ex-
posure 0.35 versus 0.30 mg/h/mL/mg. Thirty-three
patients received drug doses of 0.10–0.30mg/kg;
pharmacokinetics were dose-proportional over
this dosage range and did not vary with multiple
dosing over 15 days.[8] In clinical studies of lini-
fanib, the elimination half-life of the drug ranged
from 13.9 to 23.1 h.[9]
Phase I : Linifanib 0.25mg/kg exhibited area
under the concentration-time curve (AUC) from
time 0 to 24 hours (AUC24) values, after single
and multiple doses, of 6.2 – 1.2 mg/h/mL (mean–
SD) and 10.7 – 3.1 mg/h/mL, respectively, in pre-
liminary results from a phase I trial. The esti-
mated effective half-life value, based on observed
accumulation, was approximately 1 day. The trial
enrolled patients (n = 15) with solid tumors were
assigned to four dosing cohorts (0.05, 0.10, 0.20,
and 0.25mg/kg) of linifanib given orally once
daily on day 1 for 21 days.[10]
Preliminary data from a phase I open-label
study in nine patients with advanced or meta-
static solid tumors demonstrated a negative effect
of high fat food on linifanib pharmacokinetics
(a decrease of 43% in Cmax and 20% in AUC).
Morning dosing appears to result in higher ex-
posures than afternoon dosing (an increase of
69% in Cmax and 58% in AUC) based on data
from five patients. The terminal half-life of lini-
fanib was estimated to be approximately 1 day.[11]
In a phase I study of linifanib in patients with
refractory solid malignancies, the mean (oral)
plasma clearance of the drug was 2.8 L/h (SD –
1.2 L/h), with a corresponding mean half-life
of 16.9 hours (SD – 5 hours) with minimal drug
accumulation at day 15. Linifanib was ad-
ministered before bedtime, except on days 1 and
Table I. Features and properties
Alternate names A 741439; A-741439; A741439; ABT-869; ABT869; RG3635
Originator Abbott Laboratories
Highest development phase III (Asia, Australia, Belgium, Canada, Czech Republic, Denmark, Egypt, France, Germany, Italy, Japan, the
Netherlands, Norway, Spain, USA)
Active development-indications Acute myeloid leukemia, breast cancer, colorectal cancer, liver cancer, non-small cell lung cancer, renal
cancer
Class Indazoles, phenylurea-compounds, small-molecules, urea-compounds
Mechanism of action Protein tyrosine kinase inhibitors, proto-oncogene protein c-bcl-2 inhibitors
Chemical name N- [4-(3-amino-1H-indazol-4-yl)phenyl] -N’-(2-fluoro-5-methylphenyl)urea
Molecular formula C21 H18 F N5 O
CAS registry number 796967-16-3
Route of administration IV, PO
Pharmacodynamics Induces apoptosis of FLT-3 ITD mutant cells both in vitro and in vivo; oral preparations of linifanib in SCID
mice injected with MV-4-11 induced complete tumor regression; inhibits colony-stimulating-factor-1
receptor signaling in vitro and in vivo
ATC codes
WHO ATC code L01 (antineoplastic agents)
EphMRA ATC code L1 (antineoplastics)
Pharmacokinetics
Linear kinetics Yes
Cl (L/h) 1.5–4.1 (adult)
t½b (h) 11–23.1 (adult)
tmax (h) [oral] 2.7–3.5 (adult)
Adverse events
Rare Asthenia, erythrodysaesthesia, fatigue, hypertension, mouth disorders, muscle pain, proteinuria, skin
eruptions
Linifanib 113
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (2)
15. Six patients received a 10mg/day dose of ABT
869, 12 patients received 0.25mg/kg/day and 3
patients received 0.3mg/kg/day. The target AUC
(4.9 mg/h/mL) based on preclinical models
was achieved with daily dosing of linifanib at
10mg. A carboxylate derivative was identified as
a major metabolite, suggesting that cytochrome




Interim data from the open-label portion of
a randomized phase II trial (NCT00645177)
showed that frequent linifanib dose reductions
were required as a result of adverse events when
the compound was given in combination with
paclitaxel as first-line therapy in patients with
advanced breast cancer. Paclitaxel 90mg/m2 was
administered on days 1, 8, and 15 of every 28-day
cycle and linifanib was administered once daily
starting of day 3 of the first chemotherapy cycle.
At the time of this interim analysis, eight patients
had been enrolled, including five in the first
cohort who received linifanib 0.20mg/kg and
three in the second cohort who received linifanib
0.15mg/kg. In the first cohort, one patient
withdrew due to pulmonary embolism during
treatment cycle 2. Overall, the most frequently
reported adverse events were neutropenia (n = 3),
vomiting, increased alanine : aminotransferase
levels, stomatitis, hypertension, hypokalemia,
and hyperglycemia (n = 2 each). Most events
were grade 1/2 in severity with the exception of
neutropenia.[2]
2.2.2 Liver Cancer
In a phase II study in patients with liver can-
cer, the most common adverse events related to
linifanib were fatigue (55%) and diarrhea (48%).
Hypertension (18%) and fatigue (14%) were the
most common grade 3/4 adverse events related to
the drug. Dose interruptions and dose reductions
due to adverse events were required in 68% and
34% of patients, respectively. As of June 2010,
four patients remained on study, 27 patients dis-
continued due to progressive disease, eight due to
adverse events unrelated to progressive disease,
and five for other reasons. One death (due to
intracranial hemorrhage, day 111) was reported
to be possibly related to linifanib. The study en-
rolled 44 patients with a median age of 62 years
and 84% of whom had no prior systemic therapy.
Oral linifanib 0.25mg/kg daily or every other day
was administered until progressive disease or in-
tolerable toxicity.[3]
2.2.3 Non-Small Cell Lung Cancer
The most frequently reported adverse events
associated with linifanib (0.10mg/kg/day) ther-
apy were fatigue (35% of patients), nausea (21%),
and anorexia (21%), according to interim results
from a phase II trial (NCT00517790) in patients
with previously treated, advanced NSCLC. Ad-
verse events frequently associated with linifanib
(0.25mg/kg/day) therapywere hypertension (51%),
fatigue (51%), diarrhea (43%), anorexia (41%),
nausea (31%), proteinuria (31%), and vomiting
(26%). In recipients of linifanib (0.10mg/kg/day),
the most frequently reported grade 3/4 adverse
events were fatigue (7%), ascites (5%), dehy-
dration (5%), and pleural effusion (5%). In re-
cipients of linifanib (0.25mg/kg/day), the most
frequently reported grade 3/4 adverse events were
hypertension (23%), fatigue (8%), PPE syndrome
(8%), dyspnea (6%), and stomatitis (6%). The
majority of adverse events were mild to moderate
in severity, and were reversible with dose reduc-
tions/interruptions or discontinuation of treat-
ment.[5] Based on updated results from the study,
the most common treatment-related adverse
events were fatigue (41% of patients) and hyper-
tension (37% of patients). Hypertension was also
the most common grade 3/4 adverse events (14%
of patients). However, rates of hypertension,
proteinuria, and fatigue were lower in patients
who received low dose linifanib (0.10mg/kg/day).
Dose interruptions due to adverse events oc-
curred in 62% of patients and dose reductions to
adverse events were required in 26% of patients.
As of November 2009, seven patients remained
on study. Study discontinuations included 107
patients due to intolerable toxicity, 17 due to
adverse events not related to intolerable toxicity
and eight because of other reasons. One death
occurred from cancer erosion into pulmonary
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vessels. The study enrolled 139 patients with me-
dian age of 62 years, 60% of which had two or
more prior regimens and 12% had squamous cell
carcinoma.[4]
2.2.4 Renal Cancer
In a phase II trial in patients with renal
cell carcinoma, the most common adverse events
related to linifanib were diarrhea (74%), fatigue
(74%), hypertension (60%), nausea (51%), and
hand-foot syndrome/skin reaction (40%). Hyper-
tension was the most common linifanib-related
grade 3/4 adverse event, occurring in 32% of
patients. Dose interruptions and dose reductions
due to adverse events were required in 46 patients
and 36 patients, respectively. As of June 2010,
37 patients discontinued therapy due to pro-
gressive disease, eight due to adverse events un-
related to progressive disease and two for other
reasons. No deaths due to linifanib adverse eve-
nts were reported. In the trial, 53 patients who
have undergone previous nephrectomy, have ad-
equate organ function and have received at least
two cycles of sunitinib and stopped therapy due
to progressive disease within 100 days prior to
screening, were administered oral linifanib 0.25mg/
kg (12.5–25.0mg) daily.[6]
2.2.5 Solid Tumors
Phase II : In a phase II trial (M04-710) in
patients with refractory solid tumors who re-
ceived linifanib once daily in 21-day treatment
cycles, the following adverse events were observ-
ed for drug doses of 0.10mg/kg (n = 11) versus
0.25mg/kg (n = 12): grade 3 proteinuria (n = 2),
grade 3 hypertension (n = 1) versus grade 3 pro-
teinuria (n = 1), grade 4 proteinuria (n = 1), and
grade 3 hypertension (n = 1).[8]
In two phase II trials (M06-882 and M06-879)
in a total of 36 patients with solid tumors who
received linifanib 0.25mg/kg once daily in a
21-day cycle, grade 3 hypertension (n = 3), grade 3
fatigue (n = 1), and grade 2 proteinuria (n = 3)
were observed. Two patients in study M06-879
had received drug treatment every other day
rather than every day.[9]
Phase I :Analysis of preliminary results from a
phase I trial of linifanib showed that 15 patients
exhibited adverse events of grade 2 or higher;
hypertension (12); neutropenia (4), thrombo-
cytopenia (3), and hand foot syndrome (2). Two
patients experienced a dose limiting toxicity; one
each of grade 3 ALT increase at 0.10mg/kg and
ECG T-wave inversion at 0.25mg/kg. Patients
(n = 15) with solid tumors were assigned to four
dosing cohorts (0.05, 0.10, 0.20, and 0.25mg/kg)
of linifanib given orally once daily on day 1 for
21 days. Four patients had adverse events leading
to dose interruptions (three patients at cycle 3
and one patient at cycle 1) and one patient had an
adverse event leading to dose reduction in cycle 5.
Two patients have discontinued treatment due to
adverse events.[10]
Data from a phase I study of linifanib in
patients with refractory solid malignancies have
shown that continuous, once-daily oral dosing of
the drug was tolerable in this patient population.
Linifanib was administered before bedtime, ex-
cept on days 1 and 15. Six patients received a 10mg/
day dose of linifanib, 12 patients received 0.25mg/
kg/day and three patients received 0.3mg/kg/
day. Adverse events associated with cycle 1 of lini-
fanib included fatigue (grade 3 dose-limiting
toxicity in one patient at 10mg dose), asthenia,
myalgia (muscle pain in table 1; grade 2 in 4 of nine
patients), skin rash (maculopapular, vasculitic
in one patient), hand-foot syndrome (erythro-
dysaesthesia in table I), hypertension, proteinuria
and mouth irritation. Hypertension and protei-
nuria were reversible on dose interruption.[12,13]
In a phase I trial in patients who continued
treatment with linifanib for >1 year, the common
adverse events were myalgia and fatigue. Grade 3
adverse events related to linifanib were fatigue,
abdominal pain, and palmar-plantar erythro-
dysesthesia. No cumulative toxicities were appa-
rent with chronic dosing. Of 33 patients treated,
four received linifanib for >12 months: one pa-
tient each alveolar soft tissue sarcoma (47+
months), renal cell carcinoma (31.1 months), co-
lorectal cancer (19.9 months), and hepatocellular
cancer (15.6 months).[14]
2.2.6 Animal Toxicology
In vivo testing revealed oral linifanib (25, 12.6,
6.25mg/kg/day, twice daily for 21 days) to be well
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tolerated alone or in combination with cytotoxic
therapy (carbotaxol, irinotecan, radiation, 5-FU/
leucovorin, gemcitabine, and oxaliplatin). It also
resulted in no exacerbation of cytotoxic agent
toxicity. The study evaluated the activity of
linifanib in xenograft models (breast, colon,
head and neck squamous cell carcinoma, liver,
NSCLC, small cell lung cancer, ovarian, and
pancreatic cancer), alone or in combination with
various cytotoxic therapies.[15]
In vitro, linifanib was found to be non-toxic to
normal bone marrow progenitor cells. In vivo, no
adverse events were observed in peripheral blood




Clinical Studies :Analysis of data from a phase I
trial in patients who continued treatment with
linifanib for >1 year showed changes in indirect
vascular measurements (DCE-MRI Ktrans/circula-
ting endothelial cell) or physiological responses
to vascular endothelial growth factor inhibition.
Of 33 patients treated, four received linifanib for
>12 months: one patient each alveolar soft tissue
sarcoma (47+months), renal cell carcinoma (31.1
months), colorectal cancer (19.9 months), and
hepatocellular cancer (15.6 months).[14]
Preclinical Studies : Oral linifanib (25, 12.6,
6.25mg/kg/day, twice daily for 21 days) mono-
therapy resulted in significant tumor growth in-
hibition and the combination with cytotoxic
therapies showed significant efficacy over linifa-
nib or cytotoxic therapies alone. Further, lower
doses of linifanib in combination with cytotoxic
agents achieved similar efficacy as higher doses of
linifanib alone. The in vivo study evaluated the
activity of linifanib at clinically relevant doses in
xenograft models (breast, colon, head and neck
squamous cell carcinoma, liver, NSCLC, small
cell lung cancer, ovarian, and pancreatic cancer),
alone or in combination with various cytotoxic
therapies.[15]
In vitro, linifanib inhibited the proliferation of
Ba/F3 FLT-3 ITD mutant cells (concentration
that produces 50% inhibition [IC50] = 1 nmol/L)
when compared with Ba/F3 FLT-3 D835V mu-
tant (IC50 values between 1 and 10 nmol/L) and
Ba/F3 FLT-3 wildtype (WT) cells (IC50 = 10
mmol/L). An increase in apoptosis was demon-
strated in Ba/F3 FLT-3 ITD mutant cells treated
with 1 mmol/L ABT 869 for 24 hours (42.8%)
when compared to untreated (4.7%) or vehicle
control (4.0%) cells. Ba/F3 FLT-3 D835Vmutant
cells lines demonstrated a 12.5% rate of apoptosis
at 1 mmol/L compared to untreated (1.99%) and
vehicle control (2.1%). Poly(ADP-ribose) poly-
merase (PARP) cleavage was observed in Ba/F3
FLT-3 ITD mutant cells following 6 hours of
treatment with 1 to 100 nmol/L linifanib. No
PARP cleavage was observed in linifanib treated
Ba/F3 WT cells. In vivo, SCID mice injected with
Ba/F3 FLT-3 ITD mutant cells and treated with
vehicle control developed metastases had a me-
dian survival time of 2 weeks. The linifanib
treated group had slower disease progression
with a median survival of 6.2 weeks (p < 0.008).
Both control and treated mice injected with
Ba/F3 FLT-3 D835V mutant cell lines developed
metastases and demonstrated similar survival (a
median of 1.7 and 1.9 weeks, respectively). Sur-
vival times of control and treated mice injected
with Ba/F3 FLT-3 WT cells were also similar (a
median of 8.4 and 8.1 weeks, respectively).[7]
The combination of linifanib and subero-
ylanilide hydroxamic acid (SAHA) resulted in the
synergistic killing of acute myeloid leukemia cells
with FMS-like tyrosine kinase 3 (FLT3) muta-
tions in conventional cell culture and human
stromal cell co-culture models. A core gene sig-
nature unique to combination therapy and com-
mon to both MV4-11 and MOLM-14 cell lines
was described. The core gene signature differ-
entially inducedmore than 2-fold by combination
therapy in both cell lines included upregulation of
FRY, LM04, IFI16, ACADSB, and S100A8, and
downregulation of several genes such as PTP4A3
(PRL-3), ORC1L, MND1, and ZNF85. Over-
expression of PRL-3, a metastasis-associated
gene, has been found in different types of solid
tumors and multiple myeloma. Modulation of
PRL-3 expression level using genetic approaches
showed the role of PRL-3 in the synergistic ther-
apeutic effect of linifanib and SAHA.[17]
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Table II. History
Date Comment
25 June 2010 Phase III clinical trials in liver cancer in Asia (PO)
25 June 2010 Phase III clinical trials in liver cancer in Australia (PO)
25 June 2010 Phase III clinical trials in liver cancer in Belgium (PO)
25 June 2010 Phase III clinical trials in liver cancer in Canada (PO)
25 June 2010 Phase III clinical trials in liver cancer in Czech Republic (PO)
25 June 2010 Phase III clinical trials in liver cancer in Denmark (PO)
25 June 2010 Phase III clinical trials in liver cancer in Egypt (PO)
25 June 2010 Phase III clinical trials in liver cancer in France (PO)
25 June 2010 Phase III clinical trials in liver cancer in Germany (PO)
25 June 2010 Phase III clinical trials in liver cancer in Italy (PO)
25 June 2010 Phase III clinical trials in liver cancer in Japan (PO)
25 June 2010 Phase III clinical trials in liver cancer in the Netherlands (PO)
25 June 2010 Phase III clinical trials in liver cancer in Norway (PO)
25 June 2010 Phase III clinical trials in liver cancer in Spain (PO)
6 June 2010 Efficacy and adverse events data from a phase II trial in non-small cell lung cancer presented at the 46th Annual
Meeting of the American Society of Clinical Oncology (ASCO-2010)[4]
6 June 2010 Pharmacodynamics and adverse events data from a phase I trial in solid tumors presented at the 46th Annual
Meeting of the American Society of Clinical Oncology (ASCO-2010)[14]
4 June 2010 Efficacy and adverse events data from a phase II trial in liver cancer presented at the 46th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2010)[3]
4 June 2010 Efficacy and adverse events data from a phase II trial in renal cancer presented at the 46th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2010)[6]
10 May 2010 Phase II clinical trials in colorectal cancer in South Korea (PO)
27 March 2010 Abbott completes a phase II trial in breast cancer in the US and Mexico
24 February 2010 Abbott and Genentech complete enrollment in a phase I pharmacokinetic trial in patients with advanced or metastatic
solid tumors in the US
3 February 2010 Genentech terminates agreement with Abbott for development of linifanib
18 December 2009 Phase II clinical trials in colorectal cancer in Canada (PO)
18 December 2009 Phase II clinical trials in colorectal cancer in the EU (PO)
10 December 2009 Interim efficacy and adverse events data from a phase II trial in breast cancer presented at the 32nd Annual San
Antonio Breast Cancer Symposium (SABCS-2010)[2]
19 November 2009 Efficacy data from pooled analysis of three phase II trials in solid tumors presented at the 21st AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)[21]
19 November 2009 Interim efficacy, pharmacokinetics and adverse events data from a phase I trial in solid tumors presented at the 21st
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-
2009)[10]
19 November 2009 Pharmacodynamics and adverse events data from a preclinical trials in solid tumors presented at the 21st AACR-
NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-
2009)[15]
19 November 2009 Preliminary pharmacokinetics data from a phase I trial in cancer presented at the 21st AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)[11]
14 October 2009 Phase III clinical trials in liver cancer in the US (PO)
9 June 2009 Phase II clinical trials in colorectal cancer in Australia (PO)
2 June 2009 Interim efficacy and adverse events data from a phase II trial in non-small cell lung cancer were presented at the 45th
Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)[5]
Continued next page
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In vitro, linifanib was shown to inhibit the
phosphorylation of KDR, PDGFRb, c-Kit, and
FLT3. In vivo, linifanib showed pronounced re-
gression of established xenograft tumors. It has
been shown to be effective in human fibro-
sarcoma and human breast, colon, and small
cell lung carcinoma xenograft models with dose
that produces a 50% effective response (ED50)
Table II. Contd
Date Comment
19 April 2009 Pharmacodynamics data from a preclinical trial in cancer presented at the 100th Annual Meeting of the American
Association for Cancer Research (AACR-2009)[20]
9 December 2008 Pharmacodynamics data from preclinical trials in acute myeloid leukemia presented at the 50th Annual Meeting and
Exposition of the American Society of Hematology (ASH-2008)[7,17]
9 December 2008 Preclinical trials in acute myeloid leukemia in the US (IV)
16 September 2008 Efficacy, adverse events and pharmacokinetics data from phase I and phase II trials in solid tumors presented at the
33rd Congress of the European Society for Medical Oncology (ESMO-2008)[8,9]
31 August 2008 Phase II clinical trials in colorectal cancer in the US (PO)
30 June 2008 Phase II clinical trials in non-small cell lung cancer in combination with carboplatin/paclitaxel in Russia (PO)
30 June 2008 Phase II clinical trials in non-small cell lung cancer in combination with carboplatin/paclitaxel in the Czech Republic
(PO)
30 June 2008 Phase II clinical trials in non-small cell lung cancer in combination with carboplatin/paclitaxel in the US (PO)
30 June 2008 Phase II clinical trials in Non-small cell lung cancer in combination with paclitaxel/carboplatin in Brazil (PO)
30 June 2008 Phase II clinical trials in non-small cell lung cancer in combination with carboplatin/paclitaxel in Singapore (PO)
31 March 2008 Phase II clinical trials in breast cancer in Mexico (PO)
31 March 2008 Phase II clinical trials in breast cancer in the US (PO)
31 August 2007 Phase II clinical trials in Liver cancer in Canada (PO)
31 August 2007 Phase II clinical trials in liver cancer in Hong Kong (PO)
31 August 2007 Phase II clinical trials in liver cancer in Singapore (PO)
31 August 2007 Phase II clinical trials in liver cancer in Taiwan (PO)
31 August 2007 Phase II clinical trials in liver cancer in the US (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in Canada (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in France (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in Hong Kong (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in Singapore (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in Sweden (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in Taiwan (PO)
31 August 2007 Phase II clinical trials in non-small cell lung cancer in the US (PO)
31 August 2007 Phase II clinical trials in renal cancer in Canada (PO)
31 August 2007 Phase II clinical trials in renal cancer in the US (PO)
4 July 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the
adverse events, pharmacokinetics, and cancer therapeutic trials sections[12]
28 June 2007 Abbott Laboratories and Genetech Inc. have entered into a collaboration for the research, development and
commercialization of two of Abbott’s anti-cancer candidates, including ABT 869
8 December 2006 Clinical data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
(EORTC-NCI-AACR-2006) added to the adverse events, pharmacokinetics and Cancer therapeutic trials
sections[13]
18 January 2006 Preclinical data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-
2005) have been added to the Cancer pharmacodynamics section[16]
4 May 2005 Phase I clinical trials in cancer in the US (unspecified route)
4 May 2005 Profile created from data presented at the 96th Annual Meeting of the American Association for Cancer Research
(AACR-2005)
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values in the range 3–10mg/kg/day. Additionally,
linifanib showed a >50% inhibition of tumor
growth in orthotopic breast, prostate, and glioma
models. When given in combination with other
therapies, linifanib produced at least additive
effects.[18,19]
Further in vitro studies demonstrated that lini-
fanib at an IC50 of 10 nmol/L inhibited growth
of MV-4-11 cells (human acute myeloid leukemia
cell line that expresses FLT3-ITD) and BAF3-
ITD cells (murine B-cell line stably transfected
with the FLT3-ITD). The drug was also effective
against D835V, another FLT3 mutation, with
an IC50 of 100 nmol/L. Linifanib concentration-
dependently inhibited phosphorylation of FLT3
and activation of STAT5 and ERK downstream
signaling molecules. After 48 hours, linifanib in-
duced apoptosis, caspase-3 activation and PARP
cleavage. In vivo, oral preparations of linifanib,
20 and 40mg/kg/day in SCID mice injected with
MV-4-11 induced complete tumor regression.[16]
linifanib displayed potent activity against colony-
stimulating factor-1 receptor (CSF-1R) signaling
in vitro and in vivo. CSF-1R-dependent growth
of M-NFS-60 and RAW 264.7 cells was inhibited
by linifanib, with IC50 values of 30 and 50 nM,
respectively. The compound weakly inhibited
the IL-3-dependent growth of M-NFS-60 cells
(IC50= 4400nM) and the CSF-1-independent
growth of RAW 264.7 cells (IC50 = 8600 nM).
Sorafenib, sunitinib, cediranib, and axitinib showed
little or no separation of effects on CSF-1 and




Interim results from the initial open-label
portion of a randomized phase II trial (NCT-
00645177) demonstrated that first-line therapy
with linifanib in combination with paclitaxel may
have antitumor activity in patients with un-
resectable locally advanced or metastatic breast
cancer. Paclitaxel 90mg/m2 was administered on
days 1, 8, and 15 of every 28-day cycle and lini-
fanib was administered once daily starting of day
3 of the first chemotherapy cycle. Of the five
patients who received linifanib at 0.20mg/kg in
the first dosing cohort, two had a confirmed
partial response and continued on study treat-
ment at a reduced dose for 12 and 10 cycles,
respectively, and the other three discontinued
treatment due to disease progression in one, with-
drawal of consent in another and an adverse
event in the third. In the second dosing cohort,
three patients have been dosed with linifanib
0.15mg/kg. Two of these achieved a partial res-
ponse but the other was not evaluable at the time
of the interim analysis.[2]
Liver Cancer
In a phase II study in patients with liver can-
cer, 11 of 33 evaluable patients had decreased
PIVKA (serum protein induced by vitamin K
absence), which was associated with improved
overall survival. The study enrolled 44 patients
with a median age of 62 years and 84% of whom
had no prior systemic therapy. Oral linifanib
0.25mg/kg daily or every other day was ad-
ministered until progressive disease or intolerable
toxicity.[3]
Non-Small Cell Lung Cancer
In a phase II study (NCT00517790), linifanib
at 0.10mg/kg and 0.25mg/day was effective
in previously treated patients with advanced
or metastatic NSCLC. Progression-free rate at
16 weeks was similar in groups who received
linifanib at 0.10 and 0.25mg/kg/day (32.3% vs
36.5% of patients, respectively). In both groups,
median progression-free survival was 3.6 months,
median overall response rate was 1.4% and me-
dian overall survival was 9 months. The study
enrolled 139 patients with median age of 62 years,
60% of whom had at least two prior regimens and
12% had squamous cell carcinoma.[4] Interim re-
sults from this trial showed that linifanib 0.10 and
0.25mg/kg/day were associated with 16-week
progression free survival rates of 29% and 38%,
respectively. The objective response rate was 0%
and 7% in the linifanib (0.10mg/kg/day) and
linifanib (0.25mg/kg/day) groups, respectively.
Median time to disease progression was 110 and
19 days in the linifanib (0.10mg/kg/day) and
linifanib (0.25mg/kg/day) groups, respectively.
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Median progression-free survival duration was
112 and 108 days in the corresponding groups.[5]
Renal Cancer
In a phase II trial of linifanib in patients with
renal cell carcinoma, the overall response rate
(95% CI) based on RECIST criteria was 9.4%,
median progression-free survival was 5.4 months
and median overall survival was 13.3 months.
In the trial, 53 patients (median age of 61 years)
who have undergone previous nephrectomy, have
adequate organ function and have received at
least two cycles of sunitinib and stopped therapy
due to progressive disease within 100 days prior
to screening, were administered oral linifanib
0.25mg/kg (12.5–25.0mg) daily. All patients
had prior sunitinib and other prior treatments
included cytokines (23%), sorafenib (19%), tem-
sirolimus (4%), and bevacizumab (17%). Res-
ponse rate to prior sunitinib was 13.2%. Patients
who had one prior systemic therapy appeared to
have similar progression-free survival and overall
survival as those who had more than one prior
therapy.[6]
Solid Tumors
Phase II : In a phase II trial (M04-710) in 33
patients with refractory solid tumors who re-
ceived linifanib 0.10–0.30mg/kg once daily in
21-day treatment cycles, stable disease that lasted
for 3 months was observed in 17 patients and a
partial response in 3 patients.[8]
In three phase II trials (M06-880 [n = 42], M06-
882 [n = 18], and M06-879 [n = 18]) in a total of 78
patients with solid tumors who received linifanib
0.25mg/kg once daily in a 21-day cycle, 8 patients
experienced stable disease. Some patients in study
M06-880 had received a daily drug dose of
0.10mg/kg and two patients in study M06-879
had received drug treatment every other day
rather than every day.[9]
Phase I : In preliminary results from a phase I
trial, a partial response was observed in one
breast cancer patient receiving linifanib (0.20mg/
kg) with a 32% reduction from baseline. Two
patients have discontinued treatment due to ra-
diographic progressive disease (PD), and one due
to clinical PD. Patients (n = 15) with solid tumors
were assigned to four dosing cohorts (0.05, 0.10,
0.20, and 0.25mg/kg) of linifanib given orally
once daily on day 1 for 21 days.[10]
In a phase I study of linifanib in 21 patients
with refractory solid malignancies, two patients
with NSCLC experienced partial responses and
stable disease was observed in 12 patients after
four treatment periods. Linifanib was administered
before bedtime, except on days 1 and 15. Six
patients received a 10mg/day dose of linifanib, 12
patients received 0.25mg/kg/day and three patients
Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Breast cancer NE 31% (NYR) 27 Jul 2009
Colorectal cancer NE 31% (NYR) 27 Jul 2009
Liver cancer NE 31% (NYR) 27 Jul 2009
Non-small cell lung cancer NE 31% (NYR) 27 Jul 2009
Renal cancer NE 31% (NYR) 27 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘‘A’’ indicating significantly above average/likely to progress, ‘‘C’’ indicating
average, and ‘‘F’’ indicating significantly below average/unlikely to progress.‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability
of approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate; NYR = not yet rated.
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received 0.3mg/kg/day. The recommended phase
II dose of linifanib is 0.25mg/kg/day.[12,13]
Pooled Analysis
Phase II : The pooled analysis of three phase II
trials revealed linifanib resulted in 79 of 191
evaluable patients exhibiting amaximumCT tumor
volume decrease of >32%, which was associated
with improved overall survival and progression-
free survival (p< 0.001). Patients with a partial
response (confirmed or unconfirmed) [n = 27] had
better overall survival and progression-free survival
than those without a partial response (n = 181).
117 of 236 patients had DCE-MRI scans at base-
line and day 15, of these, 58% had baseline Ktrans
above the cutoff of 0.055 (established using the
RATTing statistical methodology – Resampling
and Aggregating Thresholds from Trees), and was
associated with improved overall survival, but not
progression-free survival. DCE-MRI response at
2 weeks was not associated with significant im-
provement in progression-free survival or overall
survival. The analysis included results from trials
in patients with hepatocellular, renal cell, and
NSCLCs.[21]
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